Compare iShares Self-Driving EV and Tech (IDRV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Novavax Inc — how do they compare? iShares Self-Driving EV and Tech trades at $35.9, while Novavax Inc trades at $7.9 (market cap $1.30B). Which is the better fit depends on your goals.
| IDRV | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $11.19 |
52-Week Low | $32.13 | $6.22 |
Market Cap | — | $1.30B |
Enterprise Value | — | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% with a bearish technical outlook as moving averages signal strong selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026, providing income potential amid market volatility.
The stock faces headwinds from technical weakness and competitive EV market dynamics. Upside depends on broader EV adoption trends and company-specific execution, while risks include regulatory changes and economic pressures. Investors should weigh the bearish signals against long-term sector growth opportunities.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
